Jorge Adeva
Impact in
Papers in
- Co-authors
- Juan W. Valle (5 shared papers)Adelaida La Casta (2 shared papers)Bruno Sangro (1 shared paper)Rossana Berardi (1 shared paper)Alessandro Bittoni (1 shared paper)Jordi Bruix (1 shared paper)Julien Edeline (1 shared paper)Massimiliano Salati (1 shared paper)
- Journals
- Clinical & Translational Oncology (4 papers)Journal of Hepatology (4 papers)Annals of Oncology (3 papers)European Journal of Cancer (3 papers)Liver International (2 papers)
- Partner nations
- SpainItalyUnited States
In The Last Decade
Jorge Adeva
34 papers receiving 2.0k citations
Jorge Adeva's Hit Papers
Peers
Comparison fields: 5 of 76
- Surgery 1.4k
- Oncology 709
- Cancer Research 245
- Pulmonary and Respiratory Medicine 402
- Hepatology 94
Countries citing papers authored by Jorge Adeva
This map shows the geographic impact of Jorge Adeva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Adeva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Adeva more than expected).
Fields of papers citing papers by Jorge Adeva
This network shows the impact of papers produced by Jorge Adeva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Adeva. The network helps show where Jorge Adeva may publish in the future.
Co-authors
The 25 scholars most cited alongside Jorge Adeva, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 808 |
| 2 | Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation Hit paper breakdown → | 2021 | 368 |
| 3 | Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry Hit paper breakdown → | 2022 | 251 |
| 4 | 2019 | 76 | |
| 5 | 2019 | 74 | |
| 6 | 2018 | 72 | |
| 7 | 2020 | 58 | |
| 8 | 2021 | 56 | |
| 9 | 2018 | 30 | |
| 10 | 2024 | 30 | |
| 11 | 2016 | 25 | |
| 12 | 2025 | 13 | |
| 13 | 2021 | 12 | |
| 14 | 2025 | 12 | |
| 15 | 2021 | 11 | |
| 16 | 2018 | 10 | |
| 17 | 2021 | 8 | |
| 18 | 2024 | 8 | |
| 19 | 2023 | 7 | |
| 20 | 2017 | 7 |
About Jorge Adeva
Jorge Adeva is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Hepatology, having authored 38 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (29 papers), Pancreatic and Hepatic Oncology Research (14 papers), Gallbladder and Bile Duct Disorders (7 papers), Peptidase Inhibition and Analysis (4 papers), Pediatric Hepatobiliary Diseases and Treatments (3 papers), Cancer Genomics and Diagnostics (2 papers), Multiple and Secondary Primary Cancers (2 papers) and Neuroendocrine Tumor Research Advances (2 papers). The work is most often cited by research in Surgery (1.4k citations), Oncology (709 citations), Cancer Research (245 citations), Pulmonary and Respiratory Medicine (402 citations) and Hepatology (94 citations). Jorge Adeva has collaborated with scholars based in Spain, Italy and United States. Frequent co-authors include Juan W. Valle, Adelaida La Casta, Bruno Sangro, Rossana Berardi, Alessandro Bittoni, Jordi Bruix, Julien Edeline, Massimiliano Salati, Francisco Javier Rupérez and Jose Antonio Lopez-Martin. Their work appears in journals such as Clinical & Translational Oncology, Journal of Hepatology, Annals of Oncology, European Journal of Cancer and Liver International.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.